By 2030, China's diabetes drug market will reach 116.7 billion yuan

Diabetes has become one of the world's chronic killers.
the prevalence of diabetes in China as high as 10.9%, equivalent to 1 in 10 people for diabetics, strengthening the prevention and treatment of diabetes is imminent.
it is understood that diabetic patients need to take drugs for life, the current diabetes treatment drugs are mainly divided into oral anti-sugar drugs and injection preparations (insulin) two major categories.
meters intranet data show that in 2019, China's public medical institutions diabetes drug market size reached 57.16 billion yuan, retail pharmacy insulin drug use size of about 12.43 billion yuan, the total diabetes market size of about 69.59 billion yuan.
From the data compiled by the industry, the top 20 products in the sales of diabetes treatment drugs in public medical institutions are all in the 2019 national health insurance catalog varieties, of which Akapo sugar tablets ranked first, with sales of 7.644 billion yuan, followed by 30 injections of men's winter insulin, with sales of 4,873 million yuan.
the top 10 products sold, including 5 insulin or insulin analogos, 2 insulin boosters, 1 insulin increaser and 1 α-glucosidease inhibitor.
as the population ages, the number of chronically ill people, including those with diabetes, increases, and urbanization accelerates, and the prevalence of chronic diseases increases, so will the demand for diabetes medications.
also support the development of the diabetes drug market, including the promotion of the graded diagnosis and treatment system, a large number of diabetes-related drugs into the scope of health insurance, collection, the new reimbursement system will further help the rapid development of the industry.
industry estimates that the size of China's diabetes treatment drug market will grow by about 7% from 2020 to 2030, reaching 116.7 billion yuan in 2030.
facing a hundred billion-dollar market cake, coupled with a low threshold, a large number of pharmaceutical companies are now layout the diabetes drug circuit.
, for example, there are currently 15 companies producing this product alone, and six manufacturers, such as Acapo sugar, produce it.
the promotion of the collection policy, or have an impact on the market pattern.
in the current three-batch collection, a capo sugar, metformin, gremethyla, Viglitin and other related diabetes treatment drugs have won the bid at low prices.
also includes the original drug.
such as Bayer's original drug Acapo sugar tablets (Baytang), the price reduction of only 0.18 yuan / tablet, will be conducive to greatly reducing the burden of patients and national health insurance.
also successfully bid for metformin in three rounds of collection.
It is worth noting that the Mimi net statistics of metformin Top10 brand has not been the winning three-round collection, according to the current round of collection rules, metformin will be divided into 2 billion shares, which also means that the competition pattern of metformin varieties or a huge change.
from the domestic diabetes treatment drug industry trends, traditional oral anti-sugar drugs, akabo sugar and metformin market share of more than 50%.
However, with the inclusion of some DPP-4 inhibitors in health insurance, such as Sigletin, Shagritin, Viglitin, Liglitatin, and Agritin, these products will grow significantly after entering the health insurance market in 2017, or gradually replace oral antisaccharides.
industry estimates that by 2030, DPP-4 inhibitors are expected to account for 42% of the market size of chemical oral antisaccharides, while the market share of acabo sugar and metformin will drop to 20% and 12%, respectively.
in terms of insulin and its like-for-likes, overall market growth has slowed in recent years, with the second-generation insulin market beginning to decline and the market size and share of third-generation insulin rising.
industry expects that by 2030, China's insulin and its similars market size will reach 33.61 billion yuan, a compound annual growth rate of 4.4%, the market share fell to 28.8%.
on the track of competitive manufacturers, the domestic diabetes market is still no and Nord, Sanofi, Lilly, Merca East four foreign giants monopolized, accounting for nearly 80% of the market share.
in recent years, however, there have been many domestic enterprises began to make efforts in this field, such as East China Medicine, Tonghua Dongbao, Gan Li Pharmaceuticals and so on.